In view of SEBI circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November, 2018 and amendments thereto (the said Circular), we wish to inform you that as on 31st March, 2026, Eiko Lifesciences ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eiko Lifesciences Ltd has submitted its annual disclosure to BSE confirming that as of 31st March 2026, it does not qualify as a "Large Corporate" under SEBI guidelines. The company states that the regulatory framework governing fund-raising through debt securities issuance — which applies only to Large Corporates — is therefore not applicable to it. Consequently, the company is not required to file initial or annual disclosures under this framework. This is a routine compliance filing pursuant to SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 and its subsequent amendments. The filing was digitally signed by Company Secretary Chintan Doshi on 9th April 2026.
Neutral for shareholders — this is a routine regulatory confirmation that the company falls below the threshold for Large Corporate classification, meaning no additional debt issuance disclosure requirements apply at this time.